Compare TSBK & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSBK | GLSI |
|---|---|---|
| Founded | 1915 | 2006 |
| Country | United States | United States |
| Employees | 280 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.0M | 327.2M |
| IPO Year | 1997 | 2020 |
| Metric | TSBK | GLSI |
|---|---|---|
| Price | $39.25 | $27.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 18.6K | ★ 116.6K |
| Earning Date | 04-28-2026 | 05-19-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 21.93 | N/A |
| EPS | ★ 1.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.30 | $7.78 |
| 52 Week High | $43.55 | $34.10 |
| Indicator | TSBK | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 41.08 | 61.75 |
| Support Level | $37.31 | $21.21 |
| Resistance Level | $39.98 | $30.08 |
| Average True Range (ATR) | 1.47 | 1.76 |
| MACD | -0.22 | 0.49 |
| Stochastic Oscillator | 42.63 | 81.15 |
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.